[BeMasher] was dissatisfied with the cost of other solutions to read his smart meter, so he made a project to read it himself using an rtl-sdr dongle. Using his hacking and reverse engineering ...

One of those articles, which graced the pages of this site a little more than seven years ago, was Getting Started with RTL-SDR. The original linked article has long since disappeared, and the ...

16 analysts have expressed a variety of opinions on BioNTech BNTX over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing varying results among patients. The hold impacts an open-label trial ...

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...

Professors Ugur Sahin and Ozlem Tureci co-founded the German company BioNTech in 2008, exploring new technology involving messenger RNA (mRNA), to treat cancer. When the pandemic struck they ...

In the latest quarter, 15 analysts provided ratings for BioNTech (NASDAQ:BNTX), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing ...

BioNTech SE reported a surprise profit in the third quarter, helped by solid sales of its variant-adapted Covid-19 vaccines. Mainz, Germany-based BioNTech posted earnings of €0.81 ($0.88) per ...

It would be easy to forget that back in 2019, BioNTech was an early-stage biotech firmly focused on cancer vaccines, before being catapulted onto the world-stage with its COVID-19 shot.

In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created ...

Pfizer and BioNTech have started clinical trials of a new Covid vaccine which targets the Omicron variant. The companies plan to test the protection gained from the new vaccine as a booster jab ...